Hypertension in Dementia – Feasibility Study
Award Number
PB-PG-1112-29070Programme
Research for Patient BenefitStatus / Stage
CompletedDates
4 February 2014 -27 July 2024
Duration (calculated)
10 years 05 monthsFunder(s)
NIHRFunding Amount
£340,023.00Funder/Grant study page
NIHRContracted Centre
Nottingham University Hospitals NHS TrustPrincipal Investigator
Dr Veronika van der WardPI Contact
V.VanDerwardt@nottingham.ac.ukPI ORCID
0000-0003-3995-7056WHO Catergories
Risk reduction interventionDisease Type
Dementia (Unspecified)CPEC Review Info
| Reference ID | 53 |
|---|---|
| Researcher | Reside Team |
| Published | 12/06/2023 |
Data
| Award Number | PB-PG-1112-29070 |
|---|---|
| Status / Stage | Completed |
| Start Date | 20140204 |
| End Date | 20240727 |
| Duration (calculated) | 10 years 05 months |
| Funder/Grant study page | NIHR |
| Contracted Centre | Nottingham University Hospitals NHS Trust |
| Funding Amount | £340,023.00 |
Abstract
While research has shown that antihypertensive treatment reduces the risk of stroke, myocardial infarction and other cardiovascular events , this has never been investigated in people with dementia. The risk for harmful effects of antihypertensive treatment, however, is higher in people with dementia compared to those without dementia. For example, some antihypertensive treatments increase the risk of falls and syncope. Although the increased risk has been established for all older people the risk is even higher for those with dementia. Furthermore, all antihypertensive medication will contribute to polypharmacy, which is already more excessive in people with dementia than in those without, and which increases the risk of multiple negative health outcomes and mortality. Research demonstrated that antihypertensive medication can be withdrawn successfully in 20% to 100% of older people without dementia. In those, the risk of negative health events and mortality is lower than for those continuing antihypertensive medication. Consequently, for people with dementia, the balance of benefits and harms of antihypertensive treatment is likely to differ from those without dementia and may not be favourable. Withdrawal of antihypertensive therapy may be feasible, safe and might reduce adverse drug effects. Ahead of a research project to investigate the balance between benefits and harms of antihypertensive treatment in people with dementia, the proposed project aims to investigate the feasibility of such a study. Our research questions therefore are: 1) can antihypertensive treatment be withdrawn successfully in people with dementia using antihypertensives? 2) What are response, exclusion and drop-out rates? 3) What are the issues regarding consent from consultees?We propose a feasibility study evaluating a withdrawal programme of antihypertensive treatment in people with dementia to answer these questions. The study will be carried out by the Universities of Nottingham and Leicester. Recruitment will take place through GP practices selecting people with moderate and severe dementia using antihypertensive medication. After consent, a research nurse will assess blood pressure levels to ensure they are within a normal range (following NICE guidelines). If blood pressure levels are outside the normal range, the GP will be informed and the patient excluded. Following baseline assessments (cognition, depression, independence, quality of life, behavioural problems, kidney function), participants will be entered into a withdrawal programme and monitored weekly. In case of hypertension recurring, the GP will be informed immediately to recommence antihypertensive treatment. Falls, syncope, healthcare worker visits, hospital and ED admissions as well as cardiovascular events will be recorded during BP monitoring visits. Follow-up assessments will take place after 6 months. Alongside this project, a qualitative study (thematic analysis) will investigate consultees issues regarding consent. Potential benefits to patients and the NHS The project will have immediate benefits for those participating as well as short and long term benefits for patients and research. All participants will benefit from regular (weekly) blood pressure monitoring. Blood tests at baseline and follow up provide additional health care. For those who can be successfully withdrawn from the antihypertensive treatment, this will reduce the risk for negative health outcomes. Benefits for patients and NHS after conclusion of the project will include an estimate of the number of people who are inappropriately on antihypertensive treatment and a clarification of issues around consenting for people with dementia. Both results can immediately inform health care policies and research.
Aims
Ahead of a research project to investigate the balance between benefits and harms of antihypertensive treatment in people with dementia, the proposed project aims to investigate the feasibility of such a study. Our research questions therefore are: 1) can antihypertensive treatment be withdrawn successfully in people with dementia using antihypertensives? 2) What are response, exclusion and drop-out rates? 3) What are the issues regarding consent from consultees?